TipRanks
Advertisement
Advertisement

DE:OND Stock Latest News

Oncopeptides earns EANO poster nod as PDC platform pushes into glioblastoma
Company AnnouncementsOncopeptides earns EANO poster nod as PDC platform pushes into glioblastoma
17d ago
Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting
PremiumCompany Announcements
Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting
17d ago
Oncopeptides Wins EMA Backing to Move Pepaxti Into Third-Line Myeloma Use
PremiumCompany Announcements
Oncopeptides Wins EMA Backing to Move Pepaxti Into Third-Line Myeloma Use
21d ago
Oncopeptides AB Earnings Call Highlights Growth Momentum
PremiumCompany Announcements
Oncopeptides AB Earnings Call Highlights Growth Momentum
1M ago
Oncopeptides lifts Q2 sales 62% and moves to double Pepaxti market in Europe
PremiumCompany Announcements
Oncopeptides lifts Q2 sales 62% and moves to double Pepaxti market in Europe
1M ago
Oncopeptides to Present Q2 2026 Results as Oncology Commercialization Expands
PremiumCompany AnnouncementsOncopeptides to Present Q2 2026 Results as Oncology Commercialization Expands
2M ago
Oncopeptides Secures Slovenian List Price for Pepaxti in First CEE Expansion Step
Premium
Company Announcements
Oncopeptides Secures Slovenian List Price for Pepaxti in First CEE Expansion Step
2M ago
Premium
Company Announcements
Oncopeptides Updates Share and Vote Structure After Incentive Share Conversion
3M ago
PremiumCompany Announcements
Oncopeptides Enrolls First Patient in Pioneering Glioblastoma PDC Trial
4M ago
PremiumCompany Announcements
Oncopeptides seeks EMA approval to move Pepaxti into earlier-line multiple myeloma treatment
4M ago
PremiumCompany Announcements
Oncopeptides launches German real-world study to bolster Pepaxti’s myeloma profile
4M ago
PremiumCompany Announcements
Oncopeptides to spotlight Pepaxti data and PDC strategy at EHA 2026
4M ago
PremiumCompany AnnouncementsOncopeptides Accelerates CEE Expansion for Pepaxti via Exclusive Salus Distribution Deal
5M ago
Premium
Company Announcements
Oncopeptides AGM Backs Incentive Schemes and Expands Capital-Raising Mandate
5M ago
Premium
Company Announcements
Oncopeptides’ Pepaxti Shows Strong Phase 2 Data in Myeloma Patients With Renal Impairment
5M ago
PremiumCompany Announcements
Oncopeptides Wins Norwegian Green Light for Pioneering Glioblastoma Trial
5M ago
PremiumCompany Announcements
Oncopeptides showcases new Pepaxti data to bolster multiple myeloma positioning
5M ago
PremiumCompany Announcements
Oncopeptides posts strong Q1 sales growth as Pepaxti momentum builds in Europe
5M ago
PremiumCompany Announcements
Oncopeptides Targets Third-Line Multiple Myeloma Indication to Boost Pepaxti Growth
5M ago
PremiumCompany AnnouncementsOncopeptides Sets May 13 Webcast for Q1 2026 Results
5M ago
Premium
Company Announcements
Oncopeptides Marks Growth Phase as 2025 Annual Report Highlights Pepaxti Momentum
5M ago
Premium
Company Announcements
Oncopeptides Sets May Date and Rules for 2026 AGM Participation
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >